The Flaxil Label (A)

Below are the available bulk discount rates for each individual item when purchase a certain amount

Register as a Premium Educator at, a course, and save your students up to 50% with your academic discount.

Publication Date:
August 24, 2008

Harvard Business School

Pharmaceutical industry

This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the label for Mytex’s blockbuster drug for arthritis, Flaxil. The negotiation is quite qualitative and differs from the typical price negotiation with which students are familiar. However, at stake was $500 million in Flaxil sales and the safety of millions of patients. The (A) case presents the perspective of Mytex and the FDA on data suggesting the Flaxil may have a side effect.

Copyright © 2021 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.

The Flaxil Label (A)

& References of The Flaxil Label (A)|A&C Accounting And Tax Services

Leave a Reply